Dzmitry Dzemidovich The U.S. FDA has approved Verona Pharma's ( NASDAQ: VRNA ) Ohtuvayre (ensifentrine) as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
Company shares are up ~20% in after-hours tradfing. Ohtuvayre is a first-in-class selective dual PDE3 and PDE4 inhibitor combining a bronchodilator with non-steroidal anti-inflammatory effects. The company expects to launch the new drug in Q3.
In May 2023, Jefferies said it saw ensifentrine achieving peak sales of $1B . More on Verona Pharma Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst Verona Pharma: Key Inflection Point Directly Ahead Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript Verona Pharma gets $650M in financing ahead of June FDA decision on COPD asset Verona Pharma GAAP EPS of -$0.04 beats by $0.
09.
